Beyond the EV Hype: Our New Review in Advanced Science

I'm pleased to share that our review article, "Beyond Extracellular Vesicle (EV) Hype: Practical Solutions and Remaining Hurdles in EV Research, Manufacturing, and Clinical Translation," has just been published in Advanced Science (Editor's Choice). You can read the full open-access article here: https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202521913.

What we set out to do

Rather than cataloguing yet more reported benefits, we focus on the practical translational issues that affect all EV indications: how preparations are defined, measured, manufactured, benchmarked, and regulated. A recurring theme is that the idealised "pure EV" does not exist with current technology — every preparation is a heterogeneous mixture of vesicle subpopulations together with non-vesicular co-isolates (lipoproteins, protein complexes, albumin, even trace metals). We argue that the "EV preparation," not an imagined pure vesicle, should be treated as the relevant unit for therapeutic development.

Challenging some popular claims

We revisit several widely repeated assumptions in light of newer, more rigorous studies. For example: links between EV cargo and downstream cargo are murkier than usually presented, internalisation of EVs into cells does not mean cargo delivery and function, and many claims of EV "targeting" are oversold.

Two parallel worlds

EVs are popular in direct-to-consumer products, from cosmetics and anti-ageing serums to clinical injectables, but they are also in legitimate IND-backed clinical trials for a handful of disorders. This is an example of where hype and marketing has moved ahead of the science.

Manufacturing

Scaling EV production from research bench to GMP clinic is one of the field's biggest practical hurdles. Upstream, moving from 2D flasks to 3D microcarriers, hollow-fiber systems, or perfusion bioreactors can boost per-cell EV yield, but it also alters cargo composition and apparent potency. Downstream, many research methods like ultracentrifugation don't scale well, pushing the field toward closed, continuous approaches such as tangential flow filtration combined with size-exclusion or anion-exchange chromatography. Encouragingly, new industrial partnerships such as Lonza–RION signal growing commercial confidence in EV biomanufacturing.

The full open-access article is here: https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202521913. Many thanks to my co-authors and to NSTC Taiwan for supporting this work.